{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "magnesium sulphate",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "Do not use Magnesium Sulfate in 5% Dextrose Injection in series connections. 2.2 Recommended Dosage • The recommended loading dosage of Magnesium Sulfate in 5% Dextrose Injection in patients with eclampsia or preeclampsia is 4 to 6 grams over 15 minutes followed by a recommended maintenance dosage of 1 to 2 grams every hour. • Obtain serum magnesium concentrations and assess clinical status to adjust the dosage.",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "The safety and effectiveness of Magnesium Sulfate in 5% Dextrose Injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. Dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see Dosage and Administration (2.2) ] .",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "For patients with recurrent eclampsia, consider giving an additional 2 gram intravenous bolus. • For patients with eclampsia, therapy should continue until seizures cease. • The maximum recommended dosage is 30 to 40 grams of magnesium sulfate over 24 hours. • Administration of Magnesium Sulfate in 5% Dextrose Injection beyond 5 to 7 days is not recommended [see Warnings and Precautions (5.1) ] .",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      },
      {
        "text": "Patients with severe renal impairment and/or a urine output less than 100 mL every 4 hours are at greater risk for increased magnesium concentrations that may lead to toxicity ( 8.6 ) 8.1 Pregnancy Risk Summary Magnesium Sulfate in 5% Dextrose Injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia.",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      },
      {
        "text": "Dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see Dosage and Administration (2.2) ] . 8.6 Renal Impairment Magnesium is excreted solely by the kidneys.",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Risk Summary Magnesium Sulfate in 5% Dextrose Injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia.",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      },
      {
        "text": "Fetal, neonatal, and maternal risks are discussed throughout the labeling.",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      },
      {
        "text": "Clinical Considerations Labor or Delivery: Magnesium Sulfate in 5% Dextrose Injection is not approved for the treatment of pre-term labor.",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Administration of Magnesium Sulfate in 5% Dextrose Injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see Warnings and Precautions (5.1) ] . 8.2 Lactation The use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor.",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      },
      {
        "text": "The developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for Magnesium Sulfate in 5% Dextrose Injection and any potential adverse effects on the breastfed infant from Magnesium Sulfate in 5% Dextrose Injection or from the underlying maternal condition.",
        "source": "US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/magnesium-sulphate.json",
        "verbatim": true
      }
    ]
  }
}